Latest Oncology Advances: Key Approvals and Late-Stage Trial Wins

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Oncology highlights include major global approvals and pivotal trial updates. Singapore approved Toripalimab for NPC, while CHMP backed Opdivo in resectable NSCLC. EMA filings for Sugemalimab and SC Keytruda mark progress in lung cancer. Notable survival gains emerged from the MARIPOSA and CABINET trials. FDA approvals expanded for Cabozantinib, Durvalumab, and Pluvicto. Japan approved TIVDAK for cervical cancer, and new late-stage ovarian cancer studies launched. These developments underscore continued innovation in immunotherapy, ADCs, radioligands, and global regulatory alignment.
Category
Oncology
Be the first to comment

Up Next